CINT vs. CPRX
CINT (CI&T Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. CINT operates in Software - Infrastructure (Technology), while CPRX operates in Biotechnology (Healthcare). Over the past 3 years, CINT returned -8.50%/yr vs 39.39%/yr for CPRX. At a 0.12 correlation, their price movements are largely independent.
Performance
CINT vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CINT achieves a -5.90% return, which is significantly lower than CPRX's 34.02% return.
CINT
- 1D
- -7.04%
- 1M
- -9.88%
- YTD
- -5.90%
- 6M
- -15.64%
- 1Y
- -34.64%
- 3Y*
- -8.50%
- 5Y*
- —
- 10Y*
- —
CPRX
- 1D
- 0.03%
- 1M
- 8.09%
- YTD
- 34.02%
- 6M
- 35.41%
- 1Y
- 25.57%
- 3Y*
- 39.39%
- 5Y*
- 41.68%
- 10Y*
- 48.24%
CINT vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CINT CI&T Inc. | -5.90% | -32.95% | 15.40% | -19.08% | -45.33% | -34.38% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.02% | 11.84% | 24.15% | -9.62% | 174.74% | 4.96% |
Correlation
The correlation between CINT and CPRX is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.10 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Nov 11, 2021 | 0.12 |
Fundamentals
CINT:
$499.42M
CPRX:
$3.97B
CINT:
$0.60
CPRX:
$1.74
CINT:
6.37
CPRX:
17.98
CINT:
0.47
CPRX:
6.67
CINT:
1.57
CPRX:
3.92
CINT:
$1.07B
CPRX:
$596.96M
CINT:
$331.71M
CPRX:
$378.23M
CINT:
$163.40M
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CINT vs. CPRX — Risk / Return Rank
CINT
CPRX
CINT vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CI&T Inc. (CINT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CINT | CPRX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.73 | 0.76 | -1.49 |
Sortino ratioReturn per unit of downside risk | -0.90 | 1.25 | -2.15 |
Omega ratioGain probability vs. loss probability | 0.89 | 1.16 | -0.27 |
Calmar ratioReturn relative to maximum drawdown | -0.77 | 0.94 | -1.71 |
Martin ratioReturn relative to average drawdown | -1.66 | 1.71 | -3.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CINT | CPRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.73 | 0.76 | -1.49 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.88 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.80 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.45 | 0.09 | -0.54 |
Drawdowns
CINT vs. CPRX - Drawdown Comparison
The maximum CINT drawdown since its inception was -83.83%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for CINT and CPRX.
Loading charts...
Drawdown Indicators
| CINT | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.83% | -94.25% | +10.42% |
Max Drawdown (1Y)Largest decline over 1 year | -46.88% | -27.29% | -19.59% |
Max Drawdown (3Y)Largest decline over 3 years | -57.72% | -27.29% | -30.43% |
Max Drawdown (5Y)Largest decline over 5 years | — | -45.37% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -64.87% | — |
Current DrawdownCurrent decline from peak | -80.83% | -0.16% | -80.67% |
Average DrawdownAverage peak-to-trough decline | -64.63% | -52.05% | -12.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.83% | 14.95% | +6.88% |
Volatility
CINT vs. CPRX - Volatility Comparison
CI&T Inc. (CINT) has a higher volatility of 22.12% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 6.81%. This indicates that CINT's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CINT | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.12% | 6.81% | +15.31% |
Volatility (6M)Calculated over the trailing 6-month period | 38.08% | 23.58% | +14.50% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.98% | 33.60% | +14.38% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.25% | 47.86% | +16.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.25% | 60.61% | +3.64% |
Dividends
CINT vs. CPRX - Dividend Comparison
Neither CINT nor CPRX has paid dividends to shareholders.
Financials
CINT vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between CI&T Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CINT vs. CPRX - Profitability Comparison
CINT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CI&T Inc. reported a gross profit of 35.75M and revenue of 136.61M. Therefore, the gross margin over that period was 26.2%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
CINT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CI&T Inc. reported an operating income of 13.71M and revenue of 136.61M, resulting in an operating margin of 10.0%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
CINT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CI&T Inc. reported a net income of 7.56M and revenue of 136.61M, resulting in a net margin of 5.5%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
CINT and CPRX have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CINT has higher volatility (22.12%) compared to CPRX (6.81%). In terms of maximum drawdown, CINT dropped -83.83% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.76 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CINT and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer